{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:24Z","timestamp":1789958844536,"version":"4.0.1"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.81873444"],"award-info":[{"award-number":["No.81873444"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>AML is an aggressive haematological malignancy characterised by uncontrolled proliferation and differentiation arrest of myeloid progenitor\/stem cells. Conventional treatment methods principally entail chemotherapy and haematopoietic stem cell transplantation; however, the efficacy of these treatments is constrained by the occurrence of relapses and treatment-related toxicity. In recent years, research into molecular mechanisms has driven the development of targeted therapies against specific gene mutations and advanced multiple immunotherapy strategies. Among these, C-type lectin-like molecule 1 (CLL-1) has emerged as a promising new immunotherapy target due to its specific expression in AML blast cells and leukemia stem cells. CLL-1-targeted therapies have been shown to have the potential to alleviate drug resistance, reduce non-specific toxicity, and address issues of immune escape. This review provides a comprehensive summary of the latest research advances in CLL-1-targeted therapies for AML, with the aim of providing novel insights and directions for clinical treatment.<\/jats:p>","DOI":"10.1007\/s00277-026-06916-2","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:53:07Z","timestamp":1773467587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CLL-1: An emerging target for immunotherapy in acute myeloid leukemia"],"prefix":"10.1007","volume":"105","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"2","key":"6916_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C et al (2021) Acute myeloid leukemia: current progress and future directions[J]. Blood Cancer J 11(2):41. https:\/\/doi.org\/10.1038\/s41408-021-00425-3","journal-title":"Blood Cancer J"},{"key":"6916_CR2","doi-asserted-by":"publisher","first-page":"107672","DOI":"10.1016\/j.leukres.2025.107672","volume":"151","author":"Q Wu","year":"2025","unstructured":"Wu Q, Zhong L, Zhang G et al (2025) Complementing therapeutic strategies for acute myeloid leukemia: Signaling pathways and targets of traditional Chinese medicine[J]. Leuk Res 151:107672. https:\/\/doi.org\/10.1016\/j.leukres.2025.107672","journal-title":"Leuk Res"},{"issue":"12","key":"6916_CR3","doi-asserted-by":"publisher","first-page":"e33165","DOI":"10.7759\/cureus.33165","volume":"14","author":"EY Arwanih","year":"2022","unstructured":"Arwanih EY, Louisa M, Rinaldi I et al (2022) Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine. Literature Review[J] Cureus 14(12):e33165. https:\/\/doi.org\/10.7759\/cureus.33165","journal-title":"Literature Review[J] Cureus"},{"issue":"6","key":"6916_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.14740\/jh1162","volume":"12","author":"JC Baena","year":"2023","unstructured":"Baena JC, Rosales MC, Estacio M et al (2023) Haploidentical and Matched Sibling Transplantation for Acute Myeloid Leukemia: A Hospital-Based Study[J]. J Hematol 12(6):255\u2013267. https:\/\/doi.org\/10.14740\/jh1162","journal-title":"J Hematol"},{"issue":"18","key":"6916_CR5","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE et al (2019) Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML[J]. N Engl J Med 381(18):1728\u20131740. https:\/\/doi.org\/10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"issue":"25","key":"6916_CR6","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S et al (2018) Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML[J]. N Engl J Med 378(25):2386\u20132398. https:\/\/doi.org\/10.1056\/NEJMoa1716984","journal-title":"N Engl J Med"},{"issue":"6","key":"6916_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA et al (2017) Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J]. Blood 130(6):722\u2013731. https:\/\/doi.org\/10.1182\/blood-2017-04-779405","journal-title":"Blood"},{"key":"6916_CR8","doi-asserted-by":"publisher","unstructured":"Damiani D, Tiribelli M (2025) Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions[J]. Int J Mol Sci 26(10). https:\/\/doi.org\/10.3390\/ijms26104571","DOI":"10.3390\/ijms26104571"},{"issue":"6","key":"6916_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy GL, Aldoss I, Foster MC et al (2021) Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia[J]. Blood 137(6):751\u2013762. https:\/\/doi.org\/10.1182\/blood.2020007732","journal-title":"Blood"},{"key":"6916_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02767-4","author":"D Pollyea","year":"2025","unstructured":"Pollyea D, Kerre T, Deeren D et al (2025) Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia[J]. Leukemia. https:\/\/doi.org\/10.1038\/s41375-025-02767-4","journal-title":"Leukemia"},{"issue":"1","key":"6916_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"SH Soleimani","year":"2025","unstructured":"Soleimani SH, Zehtabcheh S, Seraji HR et al (2025) Unveiling the potential of CLL-1: a promising target for AML therapy[J]. Biomark Res 13(1):28. https:\/\/doi.org\/10.1186\/s40364-025-00738-6","journal-title":"Biomark Res"},{"issue":"7","key":"6916_CR12","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, van Dongen GA, Kelder A et al (2007) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells[J]. Blood 110(7):2659\u20132666. https:\/\/doi.org\/10.1182\/blood-2007-03-083048","journal-title":"Blood"},{"issue":"5","key":"6916_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/bjh.15711","volume":"184","author":"M Bill","year":"2019","unstructured":"Bill M, Aggerholm A, Kjeldsen E et al (2019) Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy[J]. Br J Haematol 184(5):769\u2013781. https:\/\/doi.org\/10.1111\/bjh.15711","journal-title":"Br J Haematol"},{"key":"6916_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-065x.1998.tb01185.x","volume":"163","author":"WI Weis","year":"1998","unstructured":"Weis WI, Taylor ME, Drickamer K (1998) The C-type lectin superfamily in the immune system[J]. Immunol Rev 163:19\u201334. https:\/\/doi.org\/10.1111\/j.1600-065x.1998.tb01185.x","journal-title":"Immunol Rev"},{"key":"6916_CR15","doi-asserted-by":"publisher","first-page":"1126043","DOI":"10.3389\/fimmu.2023.1126043","volume":"14","author":"M Scur","year":"2023","unstructured":"Scur M, Parsons BD, Dey S et al (2023) The diverse roles of C-type lectin-like receptors in immunity[J]. Front Immunol 14:1126043. https:\/\/doi.org\/10.3389\/fimmu.2023.1126043","journal-title":"Front Immunol"},{"issue":"1","key":"6916_CR16","doi-asserted-by":"publisher","first-page":"32966","DOI":"10.1038\/s41598-025-16909-2","volume":"15","author":"J Szczykutowicz","year":"2025","unstructured":"Szczykutowicz J, Zimmer M, Orczyk-Pawilowicz M (2025) Amniotic fluid glycoproteins as potential ligands for macrophage galactose-type C-type lectin and their possible implications for immunoregulation during pregnancy[J]. Sci Rep 15(1):32966. https:\/\/doi.org\/10.1038\/s41598-025-16909-2","journal-title":"Sci Rep"},{"issue":"3","key":"6916_CR17","doi-asserted-by":"publisher","first-page":"105765","DOI":"10.1016\/j.jbc.2024.105765","volume":"300","author":"H Tang","year":"2024","unstructured":"Tang H, Xiao Y, Qian L et al (2024) Mechanistic insights into the C-type lectin receptor CLEC12A-mediated immune recognition of monosodium urate crystal[J]. J Biol Chem 300(3):105765. https:\/\/doi.org\/10.1016\/j.jbc.2024.105765","journal-title":"J Biol Chem"},{"issue":"22","key":"6916_CR18","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","volume":"64","author":"AB Bakker","year":"2004","unstructured":"Bakker AB, van den Oudenrijn S, Bakker AQ et al (2004) C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia[J]. Cancer Res 64(22):8443\u20138450. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1659","journal-title":"Cancer Res"},{"issue":"3","key":"6916_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2013.12.015","volume":"40","author":"K Neumann","year":"2014","unstructured":"Neumann K, Castineiras-Vilarino M, Hockendorf U et al (2014) Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death[J]. Immunity 40(3):389\u2013399. https:\/\/doi.org\/10.1016\/j.immuni.2013.12.015","journal-title":"Immunity"},{"issue":"15","key":"6916_CR20","doi-asserted-by":"publisher","first-page":"14792","DOI":"10.1074\/jbc.M313127200","volume":"279","author":"AS Marshall","year":"2004","unstructured":"Marshall AS, Willment JA, Lin HH et al (2004) Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes[J]. J Biol Chem 279(15):14792\u201314802. https:\/\/doi.org\/10.1074\/jbc.M313127200","journal-title":"J Biol Chem"},{"issue":"2","key":"6916_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cyto.b.21745","volume":"96","author":"AE Bras","year":"2019","unstructured":"Bras AE, de Haas V, van Stigt A et al (2019) CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping[J]. Cytometry Part B: Clin Cytometry 96(2):134\u2013142. https:\/\/doi.org\/10.1002\/cyto.b.21745","journal-title":"Cytometry Part B: Clin Cytometry"},{"issue":"10","key":"6916_CR22","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1080\/21645515.2020.1788299","volume":"16","author":"I Aldoss","year":"2020","unstructured":"Aldoss I, Clark M, Song JY et al (2020) Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia[J]. Hum vaccines immunotherapeutics 16(10):2341\u20132348. https:\/\/doi.org\/10.1080\/21645515.2020.1788299","journal-title":"Hum vaccines immunotherapeutics"},{"issue":"13","key":"6916_CR23","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.3390\/cancers13133214","volume":"13","author":"M Molica","year":"2021","unstructured":"Molica M, Perrone S, Mazzone C et al (2021) CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin[J]. Cancers 13(13):3214. https:\/\/doi.org\/10.3390\/cancers13133214","journal-title":"Cancers"},{"issue":"2","key":"6916_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA et al (2009) CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells[J]. Cell 138(2):286\u2013299. https:\/\/doi.org\/10.1016\/j.cell.2009.05.045","journal-title":"Cell"},{"issue":"24","key":"6916_CR25","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.3390\/cancers13246258","volume":"13","author":"L Melo Garcia","year":"2021","unstructured":"Melo Garcia L, Barab\u00e9 F (2021) Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia[J]. Cancers 13(24):6258. https:\/\/doi.org\/10.3390\/cancers13246258","journal-title":"Cancers"},{"issue":"60","key":"6916_CR26","doi-asserted-by":"publisher","first-page":"102088","DOI":"10.18632\/oncotarget.22141","volume":"8","author":"L Xu","year":"2017","unstructured":"Xu L, Xu J, Ma S et al (2017) High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity[J]. Oncotarget 8(60):102088\u2013102096. https:\/\/doi.org\/10.18632\/oncotarget.22141","journal-title":"Oncotarget"},{"issue":"6","key":"6916_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, Shima T, Takayanagi S et al (2010) TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells[J]. Cell Stem Cell 7(6):708\u2013717. https:\/\/doi.org\/10.1016\/j.stem.2010.11.014","journal-title":"Cell Stem Cell"},{"issue":"1","key":"6916_CR28","doi-asserted-by":"publisher","first-page":"e10618","DOI":"10.1136\/jitc-2024-010618","volume":"13","author":"J Wang","year":"2025","unstructured":"Wang J, Li H, Kulkarni A et al (2025) Differential impact of TIM-3 ligands on NK cell function[J]. J Immunother Cancer 13(1):e10618. https:\/\/doi.org\/10.1136\/jitc-2024-010618","journal-title":"J Immunother Cancer"},{"issue":"1","key":"6916_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","volume":"12","author":"H Ma","year":"2019","unstructured":"Ma H, Padmanabhan IS, Parmar S et al (2019) Targeting CLL-1 for acute myeloid leukemia therapy[J]. J Hematol Oncol 12(1):41. https:\/\/doi.org\/10.1186\/s13045-019-0726-5","journal-title":"J Hematol Oncol"},{"key":"6916_CR30","doi-asserted-by":"publisher","unstructured":"Wang J, Wang W, Chen H et al (2021) C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study[J]. Biomed Res Int 2021:6643948. https:\/\/doi.org\/10.1155\/2021\/6643948","DOI":"10.1155\/2021\/6643948"},{"issue":"20","key":"6916_CR31","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1089\/scd.2016.0310","volume":"26","author":"YY Wang","year":"2017","unstructured":"Wang YY, Chen WL, Weng XQ et al (2017) Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34(+) Acute Myeloid Leukemia[J]. Stem Cells Dev 26(20):1460\u20131467. https:\/\/doi.org\/10.1089\/scd.2016.0310","journal-title":"Stem Cells Dev"},{"key":"6916_CR32","doi-asserted-by":"publisher","unstructured":"Lloret-Madrid P, Chor\u00e3o P, Guerreiro M et al (2025) CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?[J]. Current oncology (Toronto, Ont.) 32(6):322. https:\/\/doi.org\/10.3390\/curroncol32060322","DOI":"10.3390\/curroncol32060322"},{"issue":"1","key":"6916_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R et al (2022) First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia[J]. J Hematol Oncol 15(1):88. https:\/\/doi.org\/10.1186\/s13045-022-01308-1","journal-title":"J Hematol Oncol"},{"issue":"7","key":"6916_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14712598.2019.1623200","volume":"19","author":"PF van Loo","year":"2019","unstructured":"van Loo PF, Hangalapura BN, Thordardottir S et al (2019) MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis[J]. Expert Opin Biol Ther 19(7):721\u2013733. https:\/\/doi.org\/10.1080\/14712598.2019.1623200","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"6916_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2450\/BloodTransfus.786","volume":"23","author":"H Wang","year":"2025","unstructured":"Wang H, Feng S, Zhu Y et al (2025) The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia[J]. Blood Transfus 23(4):338\u2013347. https:\/\/doi.org\/10.2450\/BloodTransfus.786","journal-title":"Blood Transfus"},{"issue":"1","key":"6916_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.14104","volume":"112","author":"X Wang","year":"2024","unstructured":"Wang X, Bian M, Lin G et al (2024) Tandem bispecific CD123\/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia[J]. Eur J Haematol 112(1):83\u201393. https:\/\/doi.org\/10.1111\/ejh.14104","journal-title":"Eur J Haematol"},{"issue":"12","key":"6916_CR37","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.1038\/s44319-024-00296-2","volume":"25","author":"M Malamud","year":"2024","unstructured":"Malamud M, Brown GD (2024) The Dectin-1 and Dectin-2 clusters: C-type lectin receptors with fundamental roles in immunity[J]. EMBO Rep 25(12):5239\u20135264. https:\/\/doi.org\/10.1038\/s44319-024-00296-2","journal-title":"EMBO Rep"},{"key":"6916_CR38","doi-asserted-by":"publisher","first-page":"650808","DOI":"10.3389\/fimmu.2021.650808","volume":"12","author":"G Pare","year":"2021","unstructured":"Pare G, Vitry J, Merchant ML et al (2021) The Inhibitory Receptor CLEC12A Regulates PI3K-Akt Signaling to Inhibit Neutrophil Activation and Cytokine Release[J]. Front Immunol 12:650808. https:\/\/doi.org\/10.3389\/fimmu.2021.650808","journal-title":"Front Immunol"},{"key":"6916_CR39","doi-asserted-by":"publisher","first-page":"102898","DOI":"10.1016\/j.redox.2023.102898","volume":"67","author":"M Ben-Khemis","year":"2023","unstructured":"Ben-Khemis M, Liu D, Pintard C et al (2023) TNFalpha counteracts interleukin-10 anti-inflammatory pathway through the NOX2-Lyn-SHP-1 axis in human monocytes[J]. Redox Biol 67:102898. https:\/\/doi.org\/10.1016\/j.redox.2023.102898","journal-title":"Redox Biol"},{"issue":"1","key":"6916_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41398-024-03222-1","volume":"15","author":"J Pang","year":"2025","unstructured":"Pang J, Cen C, Tian Y et al (2025) Targeting Shp2 as a therapeutic strategy for neurodegenerative diseases[J]. Transl Psychiatry 15(1):6. https:\/\/doi.org\/10.1038\/s41398-024-03222-1","journal-title":"Transl Psychiatry"},{"key":"6916_CR41","doi-asserted-by":"publisher","first-page":"102452","DOI":"10.1016\/j.redox.2022.102452","volume":"56","author":"J Liu","year":"2022","unstructured":"Liu J, Wei Y, Jia W et al (2022) Chenodeoxycholic acid suppresses AML progression through promoting lipid peroxidation via ROS\/p38 MAPK\/DGAT1 pathway and inhibiting M2 macrophage polarization[J]. Redox Biol 56:102452. https:\/\/doi.org\/10.1016\/j.redox.2022.102452","journal-title":"Redox Biol"},{"issue":"4","key":"6916_CR42","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1182\/blood-2005-08-3264","volume":"107","author":"CH Chen","year":"2006","unstructured":"Chen CH, Floyd H, Olson NE et al (2006) Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production[J]. Blood 107(4):1459\u20131467. https:\/\/doi.org\/10.1182\/blood-2005-08-3264","journal-title":"Blood"},{"key":"6916_CR43","doi-asserted-by":"publisher","first-page":"734229","DOI":"10.3389\/fimmu.2021.734229","volume":"12","author":"M Canton","year":"2021","unstructured":"Canton M, Sanchez-Rodriguez R, Spera I et al (2021) Reactive Oxygen Species in Macrophages: Sources and Targets[J]. Front Immunol 12:734229. https:\/\/doi.org\/10.3389\/fimmu.2021.734229","journal-title":"Front Immunol"},{"key":"6916_CR44","doi-asserted-by":"publisher","unstructured":"Dilly S, Romero M, Solier S et al (2023) Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor[J]. Antioxidants (Basel) 12(2). https:\/\/doi.org\/10.3390\/antiox12020440","DOI":"10.3390\/antiox12020440"},{"issue":"1","key":"6916_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3324\/haematol.2009.009811","volume":"95","author":"X Zhao","year":"2010","unstructured":"Zhao X, Singh S, Pardoux C et al (2010) Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia[J]. Haematologica 95(1):71\u201378. https:\/\/doi.org\/10.3324\/haematol.2009.009811","journal-title":"Haematologica"},{"issue":"14","key":"6916_CR46","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","volume":"2","author":"YP Jiang","year":"2018","unstructured":"Jiang YP, Liu BY, Zheng Q et al (2018) CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia[J]. Blood Adv 2(14):1738\u20131749. https:\/\/doi.org\/10.1182\/bloodadvances.2018020107","journal-title":"Blood Adv"},{"issue":"13","key":"6916_CR47","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","volume":"25","author":"E Drent","year":"2019","unstructured":"Drent E, Poels R, Ruiter R et al (2019) Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells[J]. Clin Cancer Res 25(13):4014\u20134025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2559","journal-title":"Clin Cancer Res"},{"key":"6916_CR48","doi-asserted-by":"publisher","first-page":"12109","DOI":"10.1038\/ncomms12109","volume":"7","author":"X Zhang","year":"2016","unstructured":"Zhang X, Cheng X, Yu L et al (2016) MCOLN1 is a ROS sensor in lysosomes that regulates autophagy[J]. Nat Commun 7:12109. https:\/\/doi.org\/10.1038\/ncomms12109","journal-title":"Nat Commun"},{"key":"6916_CR49","doi-asserted-by":"publisher","first-page":"1561823","DOI":"10.3389\/fimmu.2025.1561823","volume":"16","author":"B Klimovich","year":"2025","unstructured":"Klimovich B, Anton L, Jung J et al (2025) CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia[J]. Front Immunol 16:1561823. https:\/\/doi.org\/10.3389\/fimmu.2025.1561823","journal-title":"Front Immunol"},{"issue":"9","key":"6916_CR50","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nri2381","volume":"8","author":"JS Orange","year":"2008","unstructured":"Orange JS (2008) Formation and function of the lytic NK-cell immunological synapse[J]. Nat Rev Immunol 8(9):713\u2013725. https:\/\/doi.org\/10.1038\/nri2381","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"6916_CR51","doi-asserted-by":"publisher","first-page":"E175","DOI":"10.1002\/ajh.26136","volume":"96","author":"N Daver","year":"2021","unstructured":"Daver N, Salhotra A, Brandwein JM et al (2021) A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia[J]. Am J Hematol 96(5):E175\u2013E179. https:\/\/doi.org\/10.1002\/ajh.26136","journal-title":"Am J Hematol"},{"key":"6916_CR52","doi-asserted-by":"publisher","first-page":"1688057","DOI":"10.3389\/fonc.2025.1688057","volume":"15","author":"Z Tang","year":"2025","unstructured":"Tang Z, Xie Y, Zeng Y (2025) Antibody\u2013drug conjugate: a newly developed biological missile for tumor treatment[J]. Front Oncol 15:1688057. https:\/\/doi.org\/10.3389\/fonc.2025.1688057","journal-title":"Front Oncol"},{"key":"6916_CR53","doi-asserted-by":"publisher","unstructured":"Zhou Q, Kyazike J, Boudanova E et al (2021) Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues[J]. Pharmaceuticals (Basel) 14(7). https:\/\/doi.org\/10.3390\/ph14070672","DOI":"10.3390\/ph14070672"},{"issue":"40","key":"6916_CR54","doi-asserted-by":"publisher","first-page":"16101","DOI":"10.1073\/pnas.1211023109","volume":"109","author":"JY Axup","year":"2012","unstructured":"Axup JY, Bajjuri KM, Ritland M et al (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids[J]. Proc Natl Acad Sci U S A 109(40):16101\u201316106. https:\/\/doi.org\/10.1073\/pnas.1211023109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"6916_CR55","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1002\/anie.201008267","volume":"50","author":"MW Popp","year":"2011","unstructured":"Popp MW, Ploegh HL (2011) Making and breaking peptide bonds: protein engineering using sortase[J]. Angew Chem Int Ed Engl 50(22):5024\u20135032. https:\/\/doi.org\/10.1002\/anie.201008267","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"6916_CR56","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1021\/bc200212a","volume":"22","author":"CA Boswell","year":"2011","unstructured":"Boswell CA, Mundo EE, Zhang C et al (2011) Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats[J]. Bioconjug Chem 22(10):1994\u20132004. https:\/\/doi.org\/10.1021\/bc200212a","journal-title":"Bioconjug Chem"},{"issue":"10","key":"6916_CR57","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1021\/bc500357n","volume":"25","author":"LN Tumey","year":"2014","unstructured":"Tumey LN, Charati M, He T et al (2014) Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy[J]. Bioconjug Chem 25(10):1871\u20131880. https:\/\/doi.org\/10.1021\/bc500357n","journal-title":"Bioconjug Chem"},{"issue":"5","key":"6916_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C et al (2017) Strategies and challenges for the next generation of antibody\u2013drug conjugates[J]. Nat Rev Drug Discovery 16(5):315\u2013337. https:\/\/doi.org\/10.1038\/nrd.2016.268","journal-title":"Nat Rev Drug Discovery"},{"issue":"13","key":"6916_CR59","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang P, Li Z et al (2021) Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed\/Refractory Acute Myeloid Leukemia[J]. Clin Cancer Res 27(13):3549\u20133555. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4543","journal-title":"Clin Cancer Res"},{"key":"6916_CR60","doi-asserted-by":"publisher","first-page":"945","DOI":"10.2147\/IJN.S435407","volume":"19","author":"QR Qi","year":"2024","unstructured":"Qi QR, Tian H, Yue BS et al (2024) Research Progress of SN38 Drug Delivery System in Cancer Treatment[J]. Int J Nanomed 19:945\u2013964. https:\/\/doi.org\/10.2147\/IJN.S435407","journal-title":"Int J Nanomed"},{"issue":"1","key":"6916_CR61","doi-asserted-by":"publisher","first-page":"2498162","DOI":"10.1080\/19420862.2025.2498162","volume":"17","author":"M Wen","year":"2025","unstructured":"Wen M, Yu A, Park Y et al (2025) Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations[J]. mAbs 17(1):2498162. https:\/\/doi.org\/10.1080\/19420862.2025.2498162","journal-title":"mAbs"},{"key":"6916_CR62","doi-asserted-by":"publisher","first-page":"1352014","DOI":"10.3389\/fbioe.2024.1352014","volume":"12","author":"AV Madsen","year":"2024","unstructured":"Madsen AV, Pedersen LE, Kristensen P et al (2024) Design and engineering of bispecific antibodies: insights and practical considerations[J]. Front Bioeng Biotechnol 12:1352014. https:\/\/doi.org\/10.3389\/fbioe.2024.1352014","journal-title":"Front Bioeng Biotechnol"},{"issue":"8","key":"6916_CR63","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM et al (2019) Bispecific antibodies: a mechanistic review of the pipeline[J]. Nat Rev Drug Discov 18(8):585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"6916_CR64","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","volume":"13","author":"Y Sun","year":"2023","unstructured":"Sun Y, Yu X, Wang X et al (2023) Bispecific antibodies in cancer therapy: Target selection and regulatory requirements[J]. Acta Pharm Sin B 13(9):3583\u20133597. https:\/\/doi.org\/10.1016\/j.apsb.2023.05.023","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"6916_CR65","doi-asserted-by":"publisher","first-page":"1945803","DOI":"10.1080\/2162402X.2021.1945803","volume":"10","author":"H Bonnevaux","year":"2021","unstructured":"Bonnevaux H, Guerif S, Albrecht J et al (2021) Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment[J]. Oncoimmunology 10(1):1945803. https:\/\/doi.org\/10.1080\/2162402X.2021.1945803","journal-title":"Oncoimmunology"},{"issue":"13","key":"6916_CR66","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.7150\/thno.53121","volume":"11","author":"L Zhong","year":"2021","unstructured":"Zhong L, Shi W, Gan L et al (2021) Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo[J]. Theranostics 11(13):6393\u20136406. https:\/\/doi.org\/10.7150\/thno.53121","journal-title":"Theranostics"},{"issue":"9","key":"6916_CR67","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.11406\/rinketsu.63.1052","volume":"63","author":"K Takahashi","year":"2022","unstructured":"Takahashi K (2022) [Novel therapies in AML and their resistance mechanisms][J]. Rinsho Ketsueki 63(9):1052\u20131057. https:\/\/doi.org\/10.11406\/rinketsu.63.1052","journal-title":"Rinsho Ketsueki"},{"issue":"9","key":"6916_CR68","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N et al (2017) Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia[J]. N Engl J Med 376(9):836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"issue":"11","key":"6916_CR69","doi-asserted-by":"publisher","first-page":"e70046","DOI":"10.1002\/ctm2.70046","volume":"14","author":"A Zhu","year":"2024","unstructured":"Zhu A, Bai Y, Nan Y et al (2024) Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy[J]. Clin Transl Med 14(11):e70046. https:\/\/doi.org\/10.1002\/ctm2.70046","journal-title":"Clin Transl Med"},{"key":"6916_CR70","doi-asserted-by":"publisher","first-page":"896228","DOI":"10.3389\/fimmu.2022.896228","volume":"13","author":"A Ramirez-Labrada","year":"2022","unstructured":"Ramirez-Labrada A, Pesini C, Santiago L et al (2022) All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity[J]. Front Immunol 13:896228. https:\/\/doi.org\/10.3389\/fimmu.2022.896228","journal-title":"Front Immunol"},{"issue":"2","key":"6916_CR71","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","volume":"4","author":"RE Kontermann","year":"2012","unstructured":"Kontermann RE (2012) Dual targeting strategies with bispecific antibodies[J]. MAbs 4(2):182\u2013197. https:\/\/doi.org\/10.4161\/mabs.4.2.19000","journal-title":"MAbs"},{"issue":"27","key":"6916_CR72","doi-asserted-by":"publisher","first-page":"18693","DOI":"10.1074\/jbc.M113.528109","volume":"289","author":"JM Schanzer","year":"2014","unstructured":"Schanzer JM, Wartha K, Croasdale R et al (2014) A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties[J]. J Biol Chem 289(27):18693\u201318706. https:\/\/doi.org\/10.1074\/jbc.M113.528109","journal-title":"J Biol Chem"},{"issue":"5","key":"6916_CR73","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/1535-7163.MCT-17-0800","volume":"17","author":"Y Li","year":"2018","unstructured":"Li Y, Hickson JA, Ambrosi DJ et al (2018) ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models[J]. Mol Cancer Ther 17(5):1039\u20131050. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0800","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"6916_CR74","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/14712598.2022.2072209","volume":"22","author":"RP Chen","year":"2022","unstructured":"Chen RP, Shinoda K, Rampuria P et al (2022) Bispecific antibodies for immune cell retargeting against cancer[J]. Expert Opin Biol Ther 22(8):965\u2013982. https:\/\/doi.org\/10.1080\/14712598.2022.2072209","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"6916_CR75","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-024-01956-6","volume":"23","author":"L Cheng","year":"2024","unstructured":"Cheng L, Chen L, Shi Y et al (2024) Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison[J]. Mol Cancer 23(1):77. https:\/\/doi.org\/10.1186\/s12943-024-01956-6","journal-title":"Mol Cancer"},{"issue":"1","key":"6916_CR76","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12967-023-04193-5","volume":"21","author":"PL Huang","year":"2023","unstructured":"Huang PL, Kan HT, Hsu CH et al (2023) A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity[J]. J Transl Med 21(1):346. https:\/\/doi.org\/10.1186\/s12967-023-04193-5","journal-title":"J Transl Med"},{"issue":"3","key":"6916_CR77","doi-asserted-by":"publisher","first-page":"101470","DOI":"10.1016\/j.xcrm.2024.101470","volume":"5","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen G, Li X et al (2024) KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial[J]. Cell Rep Med 5(3):101470. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101470","journal-title":"Cell Rep Med"},{"key":"6916_CR78","doi-asserted-by":"publisher","first-page":"107355","DOI":"10.1016\/j.lungcan.2023.107355","volume":"184","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ma Y, Fan Y et al (2023) A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)[J]. Lung Cancer 184:107355. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107355","journal-title":"Lung Cancer"},{"issue":"1","key":"6916_CR79","doi-asserted-by":"publisher","first-page":"14397","DOI":"10.1038\/s41598-021-93842-0","volume":"11","author":"L Haber","year":"2021","unstructured":"Haber L, Olson K, Kelly MP et al (2021) Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning[J]. Sci Rep 11(1):14397. https:\/\/doi.org\/10.1038\/s41598-021-93842-0","journal-title":"Sci Rep"},{"key":"6916_CR80","doi-asserted-by":"publisher","unstructured":"Lee E, Lee S, Park S et al (2023) Asymmetric anti-CLL-1xCD3 bispecific antibody, ABL602 2\u2009+\u20091, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release[J]. J Immunother Cancer 11(10). https:\/\/doi.org\/10.1136\/jitc-2023-007494","DOI":"10.1136\/jitc-2023-007494"},{"issue":"1","key":"6916_CR81","doi-asserted-by":"publisher","first-page":"7244","DOI":"10.1038\/s41467-021-27472-5","volume":"12","author":"BA Benard","year":"2021","unstructured":"Benard BA, Leak LB, Azizi A et al (2021) Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia[J]. Nat Commun 12(1):7244. https:\/\/doi.org\/10.1038\/s41467-021-27472-5","journal-title":"Nat Commun"},{"issue":"8","key":"6916_CR82","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/17474086.2017.1346470","volume":"10","author":"KE Lindblad","year":"2017","unstructured":"Lindblad KE, Goswami M, Hourigan CS et al (2017) Immunological effects of hypomethylating agents[J]. Expert Rev Hematol 10(8):745\u2013752. https:\/\/doi.org\/10.1080\/17474086.2017.1346470","journal-title":"Expert Rev Hematol"},{"key":"6916_CR83","doi-asserted-by":"publisher","first-page":"624742","DOI":"10.3389\/fonc.2021.624742","volume":"11","author":"KK Wong","year":"2021","unstructured":"Wong KK, Hassan R, Yaacob NS (2021) Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes[J]. Front Oncol 11:624742. https:\/\/doi.org\/10.3389\/fonc.2021.624742","journal-title":"Front Oncol"},{"key":"6916_CR84","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/978-1-61779-974-7_30","volume":"907","author":"S Derer","year":"2012","unstructured":"Derer S, Kellner C, Berger S et al (2012) Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function[J]. Methods Mol Biol 907:519\u2013536. https:\/\/doi.org\/10.1007\/978-1-61779-974-7_30","journal-title":"Methods Mol Biol"},{"issue":"6","key":"6916_CR85","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","volume":"35","author":"US Arvindam","year":"2021","unstructured":"Arvindam US, van Hauten P, Schirm D et al (2021) A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells[J]. Leukemia 35(6):1586\u20131596. https:\/\/doi.org\/10.1038\/s41375-020-01065-5","journal-title":"Leukemia"},{"issue":"4","key":"6916_CR86","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1158\/2326-6066.CIR-18-0748","volume":"7","author":"E Krawczyk","year":"2019","unstructured":"Krawczyk E, Zolov SN, Huang K et al (2019) T-cell Activity against AML Improved by Dual-Targeted T Cells Stimulated through T-cell and IL7 Receptors[J]. Cancer Immunol Res 7(4):683\u2013692. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0748","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"6916_CR87","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1182\/blood-2016-08-735365","volume":"129","author":"SR Leong","year":"2017","unstructured":"Leong SR, Sukumaran S, Hristopoulos M et al (2017) An anti-CD3\/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia[J]. Blood 129(5):609\u2013618. https:\/\/doi.org\/10.1182\/blood-2016-08-735365","journal-title":"Blood"},{"issue":"3","key":"6916_CR88","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.7150\/thno.81494","volume":"13","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo A, Compte M, Alvarez-Vallina L et al (2023) When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy[J]. Theranostics 13(3):1028\u20131041. https:\/\/doi.org\/10.7150\/thno.81494","journal-title":"Theranostics"},{"key":"6916_CR89","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","volume":"1441","author":"M Felices","year":"2016","unstructured":"Felices M, Lenvik TR, Davis ZB et al (2016) Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells[J]. Methods Mol Biol 1441:333\u2013346. https:\/\/doi.org\/10.1007\/978-1-4939-3684-7_28","journal-title":"Methods Mol Biol"},{"issue":"6382","key":"6916_CR90","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU et al (2018) CAR T cell immunotherapy for human cancer[J]. Science 359(6382):1361\u20131365. https:\/\/doi.org\/10.1126\/science.aar6711","journal-title":"Science"},{"issue":"177","key":"6916_CR91","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia[J]. Sci Transl Med 5(177):177ra38. https:\/\/doi.org\/10.1126\/scitranslmed.3005930","journal-title":"Sci Transl Med"},{"issue":"1","key":"6916_CR92","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1186\/s12967-025-06608-x","volume":"23","author":"B He","year":"2025","unstructured":"He B, Lin R, Xu N et al (2025) Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial[J]. J Transl Med 23(1):594. https:\/\/doi.org\/10.1186\/s12967-025-06608-x","journal-title":"J Transl Med"},{"issue":"18","key":"6916_CR93","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y et al (2019) Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma[J]. N Engl J Med 380(18):1726\u20131737. https:\/\/doi.org\/10.1056\/NEJMoa1817226","journal-title":"N Engl J Med"},{"key":"6916_CR94","doi-asserted-by":"publisher","unstructured":"Laborda E, Mazagova M, Shao S et al (2017) Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia[J]. Int J Mol Sci 18(11). https:\/\/doi.org\/10.3390\/ijms18112259","DOI":"10.3390\/ijms18112259"},{"issue":"6","key":"6916_CR95","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00277-023-05601-y","volume":"103","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang Y, Xue S (2024) Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia[J]. Ann Hematol 103(6):1843\u20131857. https:\/\/doi.org\/10.1007\/s00277-023-05601-y","journal-title":"Ann Hematol"},{"issue":"1","key":"6916_CR96","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, Chen S, Xiao W et al (2018) CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia[J]. J Hematol Oncol 11(1):7. https:\/\/doi.org\/10.1186\/s13045-017-0553-5","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6916_CR97","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1186\/s12967-024-05705-7","volume":"22","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Bai X, Guo S et al (2024) Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia[J]. J Transl Med 22(1):888. https:\/\/doi.org\/10.1186\/s12967-024-05705-7","journal-title":"J Transl Med"},{"key":"6916_CR98","doi-asserted-by":"publisher","first-page":"929221","DOI":"10.3389\/fimmu.2022.929221","volume":"13","author":"F Nan","year":"2022","unstructured":"Nan F, Fu X, Chen X et al (2022) Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience[J]. Front Immunol 13:929221. https:\/\/doi.org\/10.3389\/fimmu.2022.929221","journal-title":"Front Immunol"},{"issue":"5","key":"6916_CR99","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00262-025-03998-1","volume":"74","author":"J Xu","year":"2025","unstructured":"Xu J, Zhang H, Zhao Y et al (2025) Infectious complications distribution following CLL1 CAR-T cell therapy for acute myeloid leukemiass[J]. Cancer Immunol Immunother 74(5):149. https:\/\/doi.org\/10.1007\/s00262-025-03998-1","journal-title":"Cancer Immunol Immunother"},{"key":"6916_CR100","doi-asserted-by":"publisher","first-page":"1392831","DOI":"10.3389\/fneur.2024.1392831","volume":"15","author":"MW Han","year":"2024","unstructured":"Han MW, Jeong SY, Suh CH et al (2024) Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis[J]. Front Neurol 15:1392831. https:\/\/doi.org\/10.3389\/fneur.2024.1392831","journal-title":"Front Neurol"},{"issue":"11","key":"6916_CR101","first-page":"5559","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang L, Meng Y, Yao H et al (2023) CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future[J]. Am J Cancer Res 13(11):5559\u20135576","journal-title":"Am J Cancer Res"},{"key":"6916_CR102","doi-asserted-by":"publisher","unstructured":"Bashiri DA, Yazdi M, Pockley AG et al (2021) NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development[J]. Cells 10(12). https:\/\/doi.org\/10.3390\/cells10123390","DOI":"10.3390\/cells10123390"},{"issue":"5","key":"6916_CR103","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.molmed.2017.03.002","volume":"23","author":"ZL Chang","year":"2017","unstructured":"Chang ZL, Chen YY, CARs (2017) Synthetic Immunoreceptors for Cancer Therapy and Beyond[J]. Trends Mol Med 23(5):430\u2013450. https:\/\/doi.org\/10.1016\/j.molmed.2017.03.002","journal-title":"Trends Mol Med"},{"issue":"1","key":"6916_CR104","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13046-025-03351-5","volume":"44","author":"E Yi","year":"2025","unstructured":"Yi E, Lee E, Park HJ et al (2025) A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells[J]. J Exp Clin Cancer Res 44(1):86. https:\/\/doi.org\/10.1186\/s13046-025-03351-5","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"6916_CR105","doi-asserted-by":"publisher","first-page":"1825177","DOI":"10.1080\/2162402X.2020.1825177","volume":"9","author":"S Grote","year":"2020","unstructured":"Grote S, Mittelstaet J, Baden C et al (2020) Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting[J]. Oncoimmunology 9(1):1825177. https:\/\/doi.org\/10.1080\/2162402X.2020.1825177","journal-title":"Oncoimmunology"},{"issue":"11","key":"6916_CR106","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jcyt.2022.07.008","volume":"24","author":"M Gurney","year":"2022","unstructured":"Gurney M, O\u2019Reilly E, Corcoran S et al (2022) Concurrent transposon engineering and CRISPR\/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells[J]. Cytotherapy 24(11):1087\u20131094. https:\/\/doi.org\/10.1016\/j.jcyt.2022.07.008","journal-title":"Cytotherapy"},{"key":"6916_CR107","doi-asserted-by":"publisher","unstructured":"Kong R, Liu B, Wang H et al (2025) CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting[J]. J Hematol Oncol 18(1):22. https:\/\/doi.org\/10.1186\/s13045-025-01677-3","DOI":"10.1186\/s13045-025-01677-3"},{"key":"6916_CR108","doi-asserted-by":"publisher","unstructured":"Simonetta F, Alvarez M, Negrin RS (2017) Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation[J]. Front Immunol 8:465. https:\/\/doi.org\/10.3389\/fimmu.2017.00465","DOI":"10.3389\/fimmu.2017.00465"},{"issue":"5","key":"6916_CR109","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei W, Liu H, Deng W et al (2025) Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial[J]. Nat Cancer 6(5):786\u2013800. https:\/\/doi.org\/10.1038\/s43018-025-00940-3","journal-title":"Nat Cancer"},{"issue":"1","key":"6916_CR110","doi-asserted-by":"publisher","first-page":"e2015030","DOI":"10.4084\/MJHID.2015.030","volume":"7","author":"AT Yacoub","year":"2015","unstructured":"Yacoub AT, Krishnan J, Acevedo IM et al (2015) Nutritionally variant streptococci bacteremia in cancer patients: a retrospective study, 1999\u20132014[J]. Mediterranean J Hematol Infect Dis 7(1):e2015030. https:\/\/doi.org\/10.4084\/MJHID.2015.030","journal-title":"Mediterranean J Hematol Infect Dis"},{"key":"6916_CR111","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2017.0196","author":"M Goedhart","year":"2018","unstructured":"Goedhart M, Cornelissen AS, Kuijk C et al (2018) nterferon-Gamma Impairs Maintenance and Alters Hematopoietic Support of Bone Marrow Mesenchymal Stromal Cells[J]. Stem Cells Dev 27(9):579\u2013589. https:\/\/doi.org\/10.1089\/scd.2017.0196"},{"key":"6916_CR112","doi-asserted-by":"publisher","first-page":"1389227","DOI":"10.3389\/fimmu.2024.1389227","volume":"15","author":"X Miao","year":"2024","unstructured":"Miao X, Shuai Y, Han Y et al (2024) Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed\/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission[J]. Front Immunol 15:1389227. https:\/\/doi.org\/10.3389\/fimmu.2024.1389227","journal-title":"Front Immunol"},{"issue":"12","key":"6916_CR113","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1038\/s41375-025-02720-5","volume":"39","author":"R Kadirkamanathan","year":"2025","unstructured":"Kadirkamanathan R, Georgiadis C, Kloos A et al (2025) Base edited universal donor CAR T-cell strategies for acute myeloid leukaemia[J]. Leukemia 39(12):2978\u20132987. https:\/\/doi.org\/10.1038\/s41375-025-02720-5","journal-title":"Leukemia"},{"issue":"10","key":"6916_CR114","doi-asserted-by":"publisher","first-page":"e12321","DOI":"10.1136\/jitc-2025-012321","volume":"13","author":"W Li","year":"2025","unstructured":"Li W, Chen J, Li J et al (2025) Envirotune-CAR-T: a hypoxia-responsive and glutamine-enhanced CAR-T cell therapy for overcoming tumor microenvironment-mediated suppression[J]. J Immunother Cancer 13(10):e12321. https:\/\/doi.org\/10.1136\/jitc-2025-012321","journal-title":"J Immunother Cancer"},{"key":"6916_CR115","doi-asserted-by":"publisher","first-page":"1155621","DOI":"10.3389\/fonc.2023.1155621","volume":"13","author":"M Matamala Montoya","year":"2023","unstructured":"Matamala Montoya M, van Slobbe GJJ, Chang J et al (2023) Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment[J]. Front Oncol 13:1155621. https:\/\/doi.org\/10.3389\/fonc.2023.1155621","journal-title":"Front Oncol"},{"key":"6916_CR116","doi-asserted-by":"publisher","first-page":"591342","DOI":"10.3389\/fonc.2020.591342","volume":"10","author":"S Wu","year":"2021","unstructured":"Wu S, Kuang H, Ke J et al (2021) Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma[J]. Front Oncol 10:591342. https:\/\/doi.org\/10.3389\/fonc.2020.591342","journal-title":"Front Oncol"},{"issue":"11","key":"6916_CR117","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.3390\/ijms20112823","volume":"20","author":"B Brodsk\u00e1","year":"2019","unstructured":"Brodsk\u00e1 B, Otev\u0159elov\u00e1 P, \u0160\u00e1lek C et al (2019) High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations[J]. Int J Mol Sci 20(11):2823. https:\/\/doi.org\/10.3390\/ijms20112823","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6916_CR118","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S et al (2019) Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study[J]. Cancer Discov 9(3):370\u2013383. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0774","journal-title":"Cancer Discov"},{"issue":"1","key":"6916_CR119","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","volume":"10","author":"J Chen","year":"2025","unstructured":"Chen J, Huang Z, Chen Y et al (2025) Lactate and lactylation in cancer[J]. Signal Transduct Target therapy 10(1):38. https:\/\/doi.org\/10.1038\/s41392-024-02082-x","journal-title":"Signal Transduct Target therapy"},{"issue":"5","key":"6916_CR120","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","volume":"33","author":"X Ma","year":"2021","unstructured":"Ma X, Xiao L, Liu L et al (2021) CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability[J]. Cell Metabol 33(5):1001\u20131012. https:\/\/doi.org\/10.1016\/j.cmet.2021.02.015","journal-title":"Cell Metabol"},{"key":"6916_CR121","doi-asserted-by":"publisher","unstructured":"Zhang Y, Feng S, Lv L et al (2025) Amino Acid Metabolism-Related Gene Kynureninase (KYNU) as a Prognostic Predictor and Regulator of Diffuse Large B-Cell Lymphoma[J]. Biochem Genet 10\u20131007. https:\/\/doi.org\/10.1007\/s10528-025-11047-w","DOI":"10.1007\/s10528-025-11047-w"},{"key":"6916_CR122","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.omto.2020.07.006","volume":"18","author":"MM Mane","year":"2020","unstructured":"Mane MM, Cohen IJ, Ackerstaff E et al (2020) Lactate Dehydrogenase A Depletion Alters MyC-CaP Tumor Metabolism, Microenvironment, and CAR T Cell Therapy[J]. Mol therapy oncolytics 18:382\u2013395. https:\/\/doi.org\/10.1016\/j.omto.2020.07.006","journal-title":"Mol therapy oncolytics"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06916-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:04:30Z","timestamp":1781640270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06916-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":122,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6916"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06916-2","relation":{"references":[{"id-type":"doi","id":"10.1089\/scd.2017.0196","asserted-by":"subject"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}